Adolor Stays in the Ring

Sometimes, the news that moves shares of biotech stocks really makes you wonder. Shares of Adolor were up as much as 18 percent after the development stage drugmaker announced that the FDA had accepted for review additional information about its lead drug, Entereg.
Motley Fool